HLB Group

HLB Group is growing into a global oncology company based on various anti-cancer drugs acquired through a global network. In line with the mid-term vision of "The Beginning of a Great Goal," it aims to market more than five anti-cancer drugs by 2025, developing best-in-class targeted cancer therapies such as "Rivosiranib" and "Combo," alongside a next-generation immunotherapy vaccine platform for cancer and allergies.